Literature DB >> 4376085

Plasma prolactin, GH, LH, FSH, TSH and testosterone during treatment of prostatic carcinoma with oestrogens.

A R Boyns, E N Cole, M E Phillips, S G Hillier, E H Cameron, K Griffiths, M Shahmanesh, R C Feneley, M Hartog.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4376085     DOI： 10.1016/0014-2964(74)90028-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  3 in total

Review 1.  Hormonal aspects of prostatic cancer: a review.

Authors:  J Waxman
Journal:  J R Soc Med       Date:  1985-02       Impact factor: 5.344

2.  Pituitary function after orchiectomy in patients with or without earlier estrogen treatment for prostatic carcinoma.

Authors:  R Tomić
Journal:  J Endocrinol Invest       Date:  1987-10       Impact factor: 4.256

Review 3.  Consensus on the key characteristics of endocrine-disrupting chemicals as a basis for hazard identification.

Authors:  Michele A La Merrill; Laura N Vandenberg; Martyn T Smith; William Goodson; Patience Browne; Heather B Patisaul; Kathryn Z Guyton; Andreas Kortenkamp; Vincent J Cogliano; Tracey J Woodruff; Linda Rieswijk; Hideko Sone; Kenneth S Korach; Andrea C Gore; Lauren Zeise; R Thomas Zoeller
Journal:  Nat Rev Endocrinol       Date:  2019-11-12       Impact factor: 43.330
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.